psychiatry and behavioral sciences Archive — Page 2 of 3

Black side-profile silhouette of a woman with windblown hair against a vivid blue background, with five glowing white gears overlaid inside her head.
July 26, 2021

Mood and cognition after chemotherapy

Validation of cognitive complaints appears to improve mood in patients with persistent chemotherapy-cognitive impairment, Vanderbilt researchers report.

Stylized black silhouette of a seated, curled figure against a bright orange background, with several gold spiral motifs inside the head.
October 19, 2020

Depression and the brain-age gap

Older depressed adults show accelerated brain aging, according to a new study from Vanderbilt researchers, who suggest that the effects of depression may speed the decline in cognitive functions in older individuals.

Multiple sagittal brain MRI scans arranged in a radiology film layout, with small technical labels throughout.
October 1, 2020

Pinpointing brain changes in psychosis

Specific regions of the thalamus — a central brain region — are smaller in adults with psychotic disorders and youth at risk for psychotic disorders and are associated with cognitive impairment.

Stylized side-profile illustration of a human head showing a glowing, interconnected brain and nervous system in blue, purple, and pink.
June 23, 2020

A connection to schizophrenia

The insula, a small region of the brain involved in diverse brain functions had widespread dysconnectivity in schizophrenia, Vanderbilt researchers found.

The words “Coping Strategies” in bold black text on a white strip revealed through torn brown paper.
May 21, 2020

Survey links employees with mental health resources

In alignment with May being Mental Health Awareness Month, Vanderbilt Behavioral Health and the Department of Psychiatry and Behavioral Sciences are offering employees an additional way to receive support for their mental health.

April 23, 2020

Clinical trial to test possible new therapy for autism deficits

Vanderbilt University Medical Center is participating in a multisite clinical trial to test a potential new medication for treating core deficits of autism spectrum disorders in children ages 2-4.